| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $4.2M | — | -45.4% |
| SG&A Expense | $1.7M | — | -81.0% |
| Operating Income | -$5.9M | — | +64.5% |
| Net Income | -$5.5M | — | +65.4% |
| EPS (Basic) | -$0.18 | — | +64.7% |
| EPS (Diluted) | -$0.18 | — | +64.7% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $42.1M | -12.2% | -35.5% |
| Current Assets | $43.3M | -12.4% | -34.9% |
| Total Assets | $45.4M | -12.2% | -33.8% |
| Current Liabilities | $7.3M | -7.8% | +3.4% |
| Total Liabilities | $43.1M | -1.8% | +0.4% |
| Stockholders' Equity | $2.3M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$5.9M | — | +22.5% |
| Capital Expenditures | $2K | — | — |
| Investing Cash Flow | -$2K | — | — |
| Financing Cash Flow | -$3K | — | -50.0% |
| Free Cash Flow | -$5.9M | — | — |
| -91.0% |